Athira Historical Income Statement
| ATHA Stock | USD 0.66 0.01 1.54% |
Historical analysis of Athira Pharma income statement accounts such as Interest Income of 2.1 M, Depreciation And Amortization of 939 K or Interest Expense of 29.4 M can show how well Athira Pharma performed in making a profits. Evaluating Athira Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Athira Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Athira Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Athira Pharma is a good buy for the upcoming year.
Athira |
About Athira Income Statement Analysis
Athira Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Athira Pharma shareholders. The income statement also shows Athira investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Athira Pharma Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Athira Pharma. It is also known as Athira Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Athira Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Athira Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.At present, Athira Pharma's Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 2.1 M, whereas Depreciation And Amortization is forecasted to decline to about 939 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 479K | 845K | 969K | 631.1K | Cost Of Revenue | 479K | 1.0M | 969K | 899.2K |
Athira Pharma income statement Correlations
Click cells to compare fundamentals
Athira Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Athira Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (295K) | (243K) | 334K | 1.8M | 2.0M | 2.1M | |
| Interest Income | 51K | 124K | 337K | 1.8M | 2.0M | 2.1M | |
| Depreciation And Amortization | 705K | 2M | 479K | 1.0M | 969K | 939.0K | |
| Interest Expense | 346K | 367K | 3K | 24.3M | 28.0M | 29.4M | |
| Selling General Administrative | 1.7M | 6.7M | 21.2M | 32.6M | 33.3M | 17.8M | |
| Other Operating Expenses | 4.7M | 18.7M | 55.2M | 88.9M | 125.5M | 131.7M | |
| Operating Income | (5.4M) | (20.0M) | (64.0M) | (104.0M) | (125.5M) | (119.2M) | |
| Net Income From Continuing Ops | (5.2M) | (20.0M) | (54.9M) | (100.8M) | (117.7M) | (111.8M) | |
| Ebit | (5.4M) | (21.0M) | (54.9M) | (95.6M) | (117.7M) | (111.8M) | |
| Research Development | 3.8M | 13.3M | 42.8M | 61.5M | 93.8M | 98.5M | |
| Ebitda | (4.7M) | (19.0M) | (54.4M) | (94.6M) | (116.7M) | (110.9M) | |
| Total Operating Expenses | 4.7M | 18.7M | 55.2M | 88.9M | 125.5M | 131.7M | |
| Income Before Tax | (5.2M) | (20.0M) | (54.9M) | (95.6M) | (117.7M) | (111.8M) | |
| Total Other Income Expense Net | 288K | 40K | 9.2M | 8.4M | 7.8M | 4.7M | |
| Net Income Applicable To Common Shares | (5.2M) | (20.0M) | (54.9M) | (95.6M) | (86.1M) | (81.8M) | |
| Net Income | (4.7M) | (18.6M) | (54.4M) | (87.3M) | (117.7M) | (111.8M) | |
| Income Tax Expense | (459K) | (1.3M) | (479K) | (8.4M) | (1.6M) | (1.7M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.48) | Return On Equity (0.85) |
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.